SSTI Digest

New Jersey and Virginia were the only two states to choose governors in November 2005, with both states having open races. Below is a description of each governor-elect's position on TBED.

New Jersey

New Jersey Gov.-elect Jon Corzine handily defeated Republican businessman Doug Forrester by winning more than 1.15 million votes (53 percent) to 956,795 votes (44 percent) in unofficial results. The governor-elect, who is currently a U.S. senator, will replace Democratic Acting Gov. Richard Codey, who will return to the state Senate as president of that chamber when Gov.-elect Corzine takes his oath of office. As the former chairman and CEO of Goldman Sachs, Senator Corzine put economic development at the top of his agenda during his campaign and said that he will streamline the state’s economic development apparatus and bring the New Jersey Economic Growth & Tourism Commission into the governor’s office.

Examining the components that would most likely be attributed directly to Acting Gov. Richard Codey's proposed $380 million Stem Cell Research Initiative, a Rutgers University study finds that, potentially, the state stands to benefit from an estimated $1.4 billion in new economic activity, approximately 20,000 new jobs, and $71.9 million in new state revenue over the next 20 years.

The authors of the study identify six areas of economic benefits to the state, including the economic impact of public expenditures; savings in health care costs; work time and productivity savings; retention and expansion of the biotechnology industry; and royalty payments to the state. The analysis is dependent upon several variables and the largest uncertainty is whether the current promise of stem cell research will actually yield effective therapies, the authors note.

Just over two months ago, Acting Gov. Richard Codey announced budget shortfalls were delaying the state's $380 million stem cell research initiative (see the April 25 issue of the Digest). Good news for at least part of the initiative, however, came last month in the form of legislation passed by the Senate, which allocated $150 million for construction of the planned world-class stem cell research facility.

Virginia Bauer, former New Jersey commerce secretary, was sworn in as CEO and secretary of the New Jersey Commerce & Economic Growth Commission.

Location-based tax incentives to encourage the clustering of technology companies in distressed areas or around research universities has grown in popularity since Michigan's smart zones were created several years ago.

Last week, New Jersey Gov. James McGreevey signed an Executive Order creating three Innovation Zones – industry clusters centered around and including the campuses of the New Jersey Institute of Technology, Rutgers University, and the University of Medicine and Dentistry of New Jersey.

The concept underlying the Innovation Zones is to create an innovation triangle – a partnership among tech-based companies, the state’s research universities, and state government. Mutual proximity is expected to lead to partnerships between businesses and universities to better meet research and development needs.

Reports suggest New Jersey Gov. James McGreevey, resigning his office in mid-November, will be named the first director of the Stem Cell Institute of New Jersey. Securing funding for the center has been a legislative priority for the Governor this year.

Dave Eater has announced his departure from the New Jersey Science and Technology Commission.

Sherrie Priesche, the science and technology advisor to New Jersey Governor James McGreevey, has been appointed as the new executive director for the New Jersey Commission on Science and Technology.

"We cannot be satisfied with simply passing stem cell research legislation."

So said New Jersey Gov. James McGreevey during his State of the Budget Address on Tuesday, proposing the state fund research specifically in the controversial area. Stem cell research holds promise for treating and curing a host of devastating diseases and disorders, including spinal cord injury, brain injury, Alzheimer's disease, stroke, Parkinson's disease, diabetes, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and coronary heart disease. The best source for human stem cells are embryos, which raises ethical questions.

New Jersey is launching a new program to stimulate new investment, business growth and job creation in the biotechnology and life sciences industries through a special fund to be established through the Business Employment Incentive Program (BEIP).

The $10 million Biotech/Life Sciences Venture Fund, to be administered by the New Jersey Economic Development Authority (EDA), will be created out of proceeds generated from an estimated $50 million BEIP bond issue. The state plans to issue the remaining $40 million in November. EDA already manages the $10 million New Jersey Technology Council Venture Fund, which also supports start-up technology companies.

John Tesoriero has left the New Jersey Commission on Science & Technology to become Associate Director of the Center for Advanced Information Processing at Rutgers University. David Eater is Acting Executive Director for the Commission as a search is conducted for a permanent replacement.

The Fourth of July might just be a paid holiday for New Jersey's tech-based economic development agency after all. Since Governor James McGreevey released his FY 2004 budget request six months ago, the New Jersey Commission on Science and Technology has been living under a June 30 death sentence. Facing a deficit forecast in excess of $4 billion, the governor had called for the elimination of the $15 million program.

The Commission, which has been the state's lead S&T organization since 1985, administers an array of programs that support academic research, technology incubators, business financing, SBIR proposal assistance, and the state's affiliate network for the Manufacturing Extension Partnership. The latest independent analysis, assessing the long-term impact of Commission activities as of 2002, revealed an economic impact of $120 million annually and job creation figures averaging approximately 750 each year.